When Every Treatment Has Failed: What a Cochrane Review Found About Stem Cells for Crohn's Disease

There is a version of Crohn's disease that most people outside the IBD community do not know exists. It is the version where the steroids stopped working, where the immunosuppressants caused problems, where the first biologic helped for a while and then stopped, where the second biologic never really got a proper hold, where the disease keeps going no matter what is tried. It is a smaller group than the statistics might suggest, but it is not a rare one, and the people living inside that experience often feel as though medicine has simply run out of options to offer them.

This article is about one of the few options that remains when the standard pathways are exhausted: hematopoietic stem cell transplantation, or HSCT. A Cochrane systematic review has examined the available evidence on this procedure for Crohn's disease. The findings are honest about both the potential and the limits.

What "Medically Refractory" Actually Means

Crohn's disease is managed through a step-up approach. The NHS describes treatment beginning with steroids to control flares, then escalating to immunosuppressants such as azathioprine, mercaptopurine, or methotrexate, and then, for those who need further treatment, to biological therapies (NHS, Crohn's disease treatment). The biologic options now include multiple classes: anti-TNF agents like infliximab and adalimumab, gut-selective integrin inhibitors like vedolizumab, and interleukin pathway inhibitors like ustekinumab and risankizumab.

Each of these steps gives most people meaningful control over their disease. But for a proportion of Crohn's patients, the disease fails to respond adequately to these treatments, or the side effects of the treatments themselves become unmanageable. When a person has tried multiple treatment classes across these categories without achieving acceptable disease control, their situation is described in clinical terms as medically refractory Crohn's disease.

This is a genuinely difficult position. It does not mean the disease is untreatable, but it does mean that the evidence-based standard pathways have been tried and have not been sufficient. The next question, what then?, is the one the Cochrane review addresses.

What Is Hematopoietic Stem Cell Transplantation?

Hematopoietic stem cells are the precursor cells that give rise to all blood and immune cells in the body. Hematopoietic stem cell transplantation is a procedure in which these cells are used to effectively rebuild a person's immune system.

For Crohn's disease, the approach that has been studied is autologous HSCT, meaning the transplant uses the patient's own stem cells. The process works in several stages. First, the patient receives medication to mobilise their bone marrow stem cells into the bloodstream, where they can be collected through a process called apheresis. Those cells are then frozen and stored. The patient then receives a course of high-dose immunosuppressive conditioning, a chemotherapy-like regimen designed to ablate the existing immune system. Finally, the stored stem cells are returned to the patient, where they rebuild the immune system over the following weeks and months.

The idea behind using autologous HSCT for Crohn's is that the rebuilt immune system, emerging from the patient's own reinfused stem cells, may no longer mount the dysregulated inflammatory response that drives the disease. In effect, the hypothesis is that resetting the immune system may reset the disease.

What the Cochrane Review Found

A Cochrane systematic review examined the evidence from available randomised trials on HSCT for people with medically refractory Crohn's disease (Bethge W et al., Cochrane Database of Systematic Reviews, pubmed:35556242).

The central trial in this body of evidence is the ASTIC trial, a multicentre randomised controlled trial that enrolled adults with active, refractory Crohn's disease and compared autologous HSCT against continued conventional immunosuppression. The ASTIC trial is the most rigorous evidence available on this question.

The trial found that its primary endpoint, sustained drug-free clinical remission at one year, was not met. The HSCT group did not achieve statistically superior rates of sustained remission compared to the control arm. This is the headline finding and it matters: HSCT did not clearly beat continued conventional treatment on the outcome that was pre-specified as the most important.

Within the data, however, some patients in the HSCT arm did show meaningful improvements in secondary outcomes, including disease activity scores and quality of life measures. This pattern, primary endpoint negative, some secondary signals, is common in complex IBD trials and does not simply cancel out the significance of what was observed.

The Cochrane review concluded that the overall evidence is of very low certainty. The number of available randomised trials is small, the sample sizes are limited, and the results do not provide a reliable basis for a clinical recommendation. The review's position is that HSCT for refractory Crohn's disease should not be adopted outside the context of well-designed clinical trials at specialist centres.

The Risks Are Real and Must Be Stated Clearly

HSCT for Crohn's disease is not a gentle procedure. The conditioning regimen involves a period of profound immunosuppression during which the patient is at serious risk of infection. Published clinical series have documented transplant-related mortality, deaths attributable to the procedure itself, at a rate of approximately 1% in this setting.

Other serious adverse events include prolonged neutropenia (critically low white blood cell counts), serious bacterial and fungal infections, and organ toxicity from the conditioning agents. The inpatient treatment period is lengthy, typically running to several weeks, and recovery extends for months.

This is an important part of the picture. For a patient who has already experienced years of active Crohn's disease, lost years of normal life, possibly undergone previous surgeries, and who has watched multiple treatments fail, a 1% mortality risk from a procedure might be a risk they are willing to accept. That is a valid, individual calculation. What matters is that the decision is made clearly and on the basis of accurate information, not desperation.

Who This Might Be Relevant For

The evidence, such as it is, was gathered in people with active, severe Crohn's disease that had failed to respond to conventional immunosuppression and who had not necessarily exhausted all biologic options at the time the trials were designed. The treatment landscape for refractory Crohn's has changed since the ASTIC trial, with newer biologic and small-molecule therapies now available.

This means that for any given patient today, the first question before even considering HSCT is whether truly all available treatment options have been evaluated. A specialist IBD centre experienced in the management of complex and refractory Crohn's disease will be best placed to determine whether that is the case.

HSCT for Crohn's disease is currently offered almost exclusively within clinical trials at a small number of specialist transplant and IBD centres in Europe and North America. It is not available through routine referral in most healthcare systems. Accessing it involves a specialist assessment and, in most cases, enrolment in a trial.

Why This Evidence Matters Even in Its Limitations

Cochrane reviews summarise the best available evidence even when that evidence is limited. The conclusion that HSCT for refractory Crohn's disease has low-certainty evidence does not mean the procedure has no role, it means the role cannot yet be defined with confidence from the existing trials.

For patients living with refractory Crohn's disease, the value of this kind of evidence summary lies partly in knowing the option exists, knowing what the honest evidence says about it, and being equipped to have an informed conversation with a specialist team. Hope that is informed by evidence is more useful than hope that is not.

The Cochrane review represents the scientific community's best current synthesis of what is known. That synthesis says: there is a signal here, it is not definitive, the risks are serious, and the right setting for this procedure is a clinical trial at a specialist centre.